Library Item Posts on Medivizor
Navigation Menu

Library Item Posts on Medivizor

Is switching first-line targeted therapy for rheumatoid arthritis within 6 months of not reaching disease remission better than a traditional approach?

Is switching first-line targeted therapy for rheumatoid arthritis within 6 months of not reaching disease remission better than a traditional approach?

Posted by on Jul 25, 2021 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated whether switching a first-line targeted therapy (TT) within 6 months of not attaining low disease activity (LDA) enhances the chance of patients with rheumatoid arthritis (RA) achieving their target at the 12-month visit. The data showed an increased chance of achieving a target of remission or LDA at the...

Read More

Comparing second-line therapy options combined with metformin for patients with type 2 diabetes.

Comparing second-line therapy options combined with metformin for patients with type 2 diabetes.

Posted by on Jul 25, 2021 in Diabetes mellitus | 0 comments

In a nutshell This study explored the effects of different second-line therapies combined with metformin (Glucophage) in patients with type 2 diabetes (T2D). The data showed that metformin combinations with a sulfonylurea (SU) had the lowest weight loss, the smallest effect of lowering blood glucose, and an overall, reduced health...

Read More

Does a higher dose of dasatinib increase chances of patients with Philadelphia chromosome positive acute lymphoblastic leukemia at risk for CNS relapse?

Does a higher dose of dasatinib increase chances of patients with Philadelphia chromosome positive acute lymphoblastic leukemia at risk for CNS relapse?

Posted by on Jul 25, 2021 in Leukemia | 0 comments

In a nutshell The study aimed to investigate the ability of dasatinib (Sprycel) to penetrate the brain in patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) at risk for central nervous system (CNS; brain and spinal cord) relapse.   This study concluded that a dose of 140mg per day...

Read More

Comparing outcomes of donors for a second allogenic stem cell transplant for patients with acute lymphoblastic leukemia

Comparing outcomes of donors for a second allogenic stem cell transplant for patients with acute lymphoblastic leukemia

Posted by on Jul 25, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to compare outcomes of donor types for a second allogeneic stem cell transplant (alloSCT) in patients with relapsed acute lymphoblastic leukemia (ALL).  This study concluded that there is no major difference in overall survival between a matched unrelated donor (MUD) and a half-matched donor (HMD) in...

Read More

Health-related quality of life in patients with chronic lymphocytic leukemia treated with venetoclax-obinutuzumab

Health-related quality of life in patients with chronic lymphocytic leukemia treated with venetoclax-obinutuzumab

Posted by on Jul 25, 2021 in Leukemia | 0 comments

In a nutshell The study aimed to investigate the health-related quality of life (HR-QoL) for patients with chronic lymphocytic leukemia (CLL) who were treated with venetoclax (VEN; Venclexta) and obinutuzumab (Obi; Gazyva).  This study concluded that this treatment is effective and does not impair the quality of life in these...

Read More

Evaluating the effectiveness and safety of anlotinib for unresponsive metastatic colorectal cancer.

Evaluating the effectiveness and safety of anlotinib for unresponsive metastatic colorectal cancer.

Posted by on Jul 25, 2021 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of anlotinib (AL3818) for the treatment of patients with unresponsive metastatic colorectal cancer (mCRC). The data showed that anlotinib was safe and significantly improved survival without cancer progression for these patients. Some background Colorectal cancer (CRC) is one of...

Read More

Does neratinib plus capecitabine benefit patients with HER2-positive breast cancer spread to the central nervous system?

Does neratinib plus capecitabine benefit patients with HER2-positive breast cancer spread to the central nervous system?

Posted by on Jul 25, 2021 in Breast cancer | 0 comments

In a nutshell This study compared the safety and effectiveness of neratinib (Nerlynx) plus capecitabine (Xeloda) versus lapatinib (Tykerb) plus capecitabine in patients with human epidermal growth factor (HER2)-positive breast cancer (BC) spread (metastases) to the central nervous system (CNS; brain and spinal cord). The data showed that the...

Read More

Can eye drops with citicoline and vitamin B12 help to prevent worsening of diabetic eye disease?

Can eye drops with citicoline and vitamin B12 help to prevent worsening of diabetic eye disease?

Posted by on Jul 25, 2021 in Diabetes mellitus | 0 comments

In a nutshell This study looked at the use of citicoline and vitamin B12 eye drops (OMK2) to prevent diabetic retinopathy (DR; eye disease) in patients with type 1 diabetes (T1D). It found that using these drops for 36 months improved eye function tests.  Some background Type 1 diabetes (T1D) is a common cause of blindness through...

Read More

Which factors could predict immunotherapy outcomes in patients with advanced melanoma?

Which factors could predict immunotherapy outcomes in patients with advanced melanoma?

Posted by on Jul 24, 2021 in Melanoma | 0 comments

In a nutshell This study evaluated if there were any clinical indicators to identify which patients with advanced melanoma would benefit from immune checkpoint blocker (ICB) therapy. The data showed that blood LDH levels, the extent of disease, number of white blood cells, and immune-related side effects were all associated with better...

Read More

Is pyrotinib with vinorelbine effective in treating HER2+ metastatic breast cancer?

Is pyrotinib with vinorelbine effective in treating HER2+ metastatic breast cancer?

Posted by on Jul 21, 2021 in Breast cancer | 0 comments

In a nutshell This study was carried out to examine the safety and effectiveness of pyrotinib (Irene) in combination with vinorelbine (Navelibine) is in treating metastatic breast cancer (BC). The authors found that this treatment combination showed promising results and was well tolerated in these patients.  Some background BC is...

Read More

Mental effects and depression induced by taxane-based chemotherapy in breast cancer survivors

Mental effects and depression induced by taxane-based chemotherapy in breast cancer survivors

Posted by on Jul 21, 2021 in Breast cancer | 0 comments

In a nutshell This study aimed to investigate depression and cognitive (thinking and reasoning) functions after taxane-based chemotherapy in patients with breast cancer.  This study concluded taxane-based chemotherapy commonly leads to cognitive impairment in these patients, but some functions improve or remain stable after stopping...

Read More

Reviewing effectiveness and safety of greenlight photo-selective vaporization of the prostate in patients with benign prostatic hyperplasia.

Reviewing effectiveness and safety of greenlight photo-selective vaporization of the prostate in patients with benign prostatic hyperplasia.

Posted by on Jul 21, 2021 in Benign prostatic hyperplasia | 0 comments

In a nutshell This study characterized the safety and effectiveness of greenlight photo-selective vaporization of the prostate (GL-PVP) in the treatment of benign prostatic hyperplasia (BPH). The data showed that under real-world conditions, GL-PVP provides a safe, effective, and durable BPH treatment option. Some background Lower urinary tract...

Read More